Home › Merck Announces Results From Phase 3 Studies of ZEPATIER (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress
 

Keywords :   


Merck Announces Results From Phase 3 Studies of ZEPATIER (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress

2016-04-16 07:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3 clinical trials evaluating ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets in chronic hepatitis C (HCV) patients with inherited blood disorders (C-EDGE IBLD) and in patients with a history of intravenous drug use who are receiving opioid agonist therapy (C-EDGE CO-STAR), respectively. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the results international studies

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »